Schrödinger
SDGR | NASDAQ
$27.36
-$2.17 (-7.35%)
At close: Nov 16, 2026, 4:00 PM ET
$27.43
+$0.07 (+0.26%)
After-hours:
Nov 16, 2026, 7:49 PM ET
Schrödinger Company Profile
Company profile explainedCompany Profile
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Ramy Farid | Chief Executive Officer, President & Director |
| Kenneth Patrick Lorton | Executive Vice President, Chief Technology Officer & Chief Operating Officer of Software |
| Richie Jain | Executive Vice President, Chief Financial Officer & Treasurer |
| Shane Brauner | Executive Vice President & Chief Information Officer |
| Jaren Irene Madden | Chief Corporate Affairs Officer & Head of Investor Relations |
| Karen Akinsanya | President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships |
| Richard A. Friesner | Co-Founder, Scientific Advisory Chairman and Director |
| Therese Abrams | Principal Accounting Officer |
| William Goddard | Co-Founder & Scientific Advisor |
| Yvonne Tran | Corporate Secretary, Chief Legal & People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 21, 2026 | 4 | Filing |
| Sep 17, 2026 | 144 | Filing |
| Aug 05, 2026 | S-8 | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 17, 2026 | 4 | Filing |
| Jul 16, 2026 | 144 | Filing |
| Jul 01, 2026 | 144 | Filing |
| Jun 29, 2026 | 4 | Filing |
| Jun 29, 2026 | 8-K | Current Report |
Schrödinger
| Country | United States |
| IPO Date | Feb 5, 2020 |
| Industry | Software - Application |
| Sector | Technology |
| Employees | 850 |
| CEO | Ramy Farid |
Contact Details
1540 Broadway New York,
New York 10036 United States
Stock Details
| Ticker Symbol | SDGR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001490978 |
| CUSIP Number | 80810D103 |
| ISIN Number | US80810D1037 |
| SIC Code | 2834 |
Recent News
- 6 days ago / seekingalpha.comSchrödinger, Inc. (SDGR) Presents at 2026 UBS Global Healthcare Conference Transcript
- 12 days ago / seekingalpha.comSchrödinger, Inc. (SDGR) Q3 2026 Earnings Call Transcript
- 12 days ago / marketbeat.comWhat Schrodinger (SDGR) Said on Its Q3 Earnings Call
- 12 days ago / zacks.comSchrodinger, Inc. (SDGR) Reports Q3 Loss, Beats Revenue Estimates
- 20 days ago / zacks.comEarnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline
- 20 days ago / businesswire.comSchrödinger to Present at UBS Global Healthcare Conference
- 22 days ago / businesswire.comSchrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 1 month ago / businesswire.comSchrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry
- 1 month ago / gurufocus.comSchrodinger Inc (SDGR) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 72/100
- 1 month ago / zacks.comSchrodinger (SDGR) Surges 7.6%: Is This an Indication of Further Gains?
Add to Watchlist
Select watchlists to add or remove SDGR